- Home
- CRIS vs PWM Comparison
CRIS vs PWM Comparison
Compare CRIS & PWM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRIS
- PWM
- Stock Information
- Founded
- CRIS 2000
- PWM 2018
- Country
- CRIS United States
- PWM Hong Kong
- Employees
- CRIS N/A
- PWM N/A
- Industry
- CRIS Biotechnology: Biological Products (No Diagnostic Substances)
- PWM
- Sector
- CRIS Health Care
- PWM
- Exchange
- CRIS Nasdaq
- PWM Nasdaq
- Market Cap
- CRIS 32.8M
- PWM 34.6M
- IPO Year
- CRIS 2000
- PWM 2023
- Fundamental
- Price
- CRIS $3.29
- PWM $1.73
- Analyst Decision
- CRIS Strong Buy
- PWM
- Analyst Count
- CRIS 3
- PWM 0
- Target Price
- CRIS $23.00
- PWM N/A
- AVG Volume (30 Days)
- CRIS 243.3K
- PWM 1.1M
- Earning Date
- CRIS 02-06-2025
- PWM 01-24-2025
- Dividend Yield
- CRIS N/A
- PWM N/A
- EPS Growth
- CRIS N/A
- PWM N/A
- EPS
- CRIS N/A
- PWM N/A
- Revenue
- CRIS $10,259,000.00
- PWM $348,528.00
- Revenue This Year
- CRIS N/A
- PWM N/A
- Revenue Next Year
- CRIS N/A
- PWM N/A
- P/E Ratio
- CRIS N/A
- PWM N/A
- Revenue Growth
- CRIS 0.44
- PWM N/A
- 52 Week Low
- CRIS $2.86
- PWM $0.67
- 52 Week High
- CRIS $17.49
- PWM $2.40
- Technical
- Relative Strength Index (RSI)
- CRIS 44.97
- PWM 61.42
- Support Level
- CRIS $3.10
- PWM $1.37
- Resistance Level
- CRIS $3.60
- PWM $1.55
- Average True Range (ATR)
- CRIS 0.37
- PWM 0.24
- MACD
- CRIS 0.00
- PWM 0.02
- Stochastic Oscillator
- CRIS 26.22
- PWM 88.34
About CRIS Curis Inc.
Curis Inc is a biotechnology company that develops and commercializes innovative drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, advanced solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.
About PWM Prestige Wealth Inc.
Prestige Wealth Inc is engaged in providing private wealth management services and asset management to high-net-worth and ultra-high-net-worth individuals and enterprises through its subsidiaries.